Article
Clinical significance of CYP2C19 polymorphisms on the metabolism and pharmacokinetics of 11β-hydroxysteroid dehydrogenase type-1 inhibitor BMS-823778.
British journal of clinical pharmacology - 1 Jan 2018
Cheng Yaofeng, Wang Lifei, Iacono Lisa, Zhang Donglu, Chen Weiqi, Gong Jiachang, Humphreys William Griffith, Gan Jinping
Abstract excerpt
AIMS: BMS-823778 is an inhibitor of 11β-hydroxysteroid dehydrogenase type-1, and thus a potential candidate for Type 2 diabetes treatment. Here, we investigated the metabolism and pharmacokinetics of BMS-823778 to understand its pharmacokinetic variations in early clinical trials. METHODS: The metabolism of BMS-823778 was characterized in multiple in vitro assays. Pharmacokinetics were evaluated in healthy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
